Starboard Value Purchases A $1B Stake In Pfizer, Increasing Pressure on The Drugmaker’s Management
After a booming few years for companies, activist investors are knocking at the door — and they’ve found the audacity to make demands. In the latest boardroom drama, Starboard Value has acquired a $1B stake in Pfizer. This move comes as the struggling drugmaker grapples with a post-pandemic hangover due to steep revenue declines and poor cost management. Starboard’s intervention aims to revitalize the pharmaceuticals leader recognized for its groundbreaking vaccines and restore its former success by correcting its strategy.
- Since 2020, Pfizer shifted from cutting costs to spending $70B on mergers and acquisitions, including a problematic $5B purchase of Global Blood Therapeutics, which fell short of expectations.
- Pfizer’s stock price has dropped over 50% from its Dec. 2021 peak, wiping out over $100B in shareholder value since the end of the COVID surge.
Past traditions, new direction: While Starboard’s specific demands are mostly confidential, it’s clear they want the innovative biopharma firm to concentrate on cost discipline and profitable innovation. Starboard is tapping into Pfizer’s past, courting former CEO Ian Read and ex-CFO Frank D’Amelio to aid in its turnaround efforts. This strategy harks back to a time when the pioneering drug manufacturer was celebrated for its efficient business practices. Despite Pfizer’s attempts to slash costs through a $4B program and other cutbacks, Starboard believes more drastic changes are needed.
